Global molecular diagnostics market offers great potential for growth owing to the technological progress, development of new technologies, the growth of the number of cases of infectious diseases, and the utilization of individualized medicine. Molecular diagnostics includes detection and characterization of disease biomolecules ranging from genetic markers, proteins, and other analytes. This market is extensive, and it covers areas such as infectious diseases, oncology, genetic disorders, pharmacogenomics and many more.
Global Molecular Diagnostics Market size was valued at USD 15.8 billion in 2023 and is poised to grow from USD 16.89 billion in 2024 to USD 28.8 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032). Some of the major players in the global molecular diagnostics market are the Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Qiagen N. V. and Thermo Fisher Scientific Inc. These companies are continually engaging in the strategies like mergers/net acquisitions, new products launches and strategic alliances to enhance their market position and offering portfolio.
Modern progress in molecular diagnosis led to the creation of new technologies: PCR, NGS, microarray in the recent years within the molecular diagnostics market. These innovations have thus resulted in increased sensitivity of tests and specificity of the diseases they diagnose, alongside increased multiplexing capabilities thus faster and accurate diagnosis of diseases. The molecular diagnostics market is growing significantly in the global market, especially with the increasing rates of infectious diseases like HIV, hepatitis, and respiratory infections. The molecular diagnostics market is currently undergoing significant growth in the worldwide market, particularly with the rising instances of infectious diseases including HIV, hepatitis, and respiratory infections. Besides, the global population is aging, and the prevalence of chronic diseases such as cancer and inherited disorders is growing, which necessitates effective molecular diagnostics tests for early identification and targeted therapeutic interventions.
Get a Free Sample PDF of the Report – http://www.skyquestt.com/sample-request/molecular-diagnostics-market
Molecular Diagnostics Key Market Trends:
Shift towards Point-of-Care Testing: There is a growing trend towards point-of-care molecular testing, driven by the need for rapid diagnosis and treatment monitoring in various healthcare settings, including clinics, emergency rooms, and ambulances. Miniaturized and portable molecular diagnostic devices are being developed to enable real-time testing outside traditional laboratory settings, enhancing patient care and healthcare efficiency.
Integration of Artificial Intelligence (AI) and Big Data Analytics: The integration of AI and big data analytics in molecular diagnostics is revolutionizing data interpretation, enabling more accurate and personalized diagnosis and treatment strategies. Machine learning algorithms can analyze vast amounts of genomic data to identify disease patterns, predict treatment responses, and optimize therapeutic outcomes. This trend is expected to accelerate the adoption of molecular diagnostics in precision medicine and improve patient outcomes.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Molecular Diagnostics Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Global Molecular Diagnostics Market is segmented by Product, Test Type, Sample Type, Technology, Application, End User and region.
Based on Product, the market is segmented into Reagents & Kits, Instruments and Services & Software.
Based on Test Type, the market is segmented into Lab Tests and POC Tests.
Based on Sample Type, the market is segmented into Blood, Serum, And Plasma, Urine and Other Sample Types.
Based on Technology, the market is segmented into Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing & Next-Generation Sequencing, In Situ Hybridization, DNA Microarrays and Other Technologies.
Based on Application, the market is segmented into Infectious Disease Diagnostics, Oncology Testing, Genetic Testing and Other Applications.
Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics and Other End Users.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Molecular Diagnostics Market – Regional Analysis:
North America come up as the largest market and held a 39% share in 2023. This can be attributed to the increasing incidence of both infectious and chronic diseases; such trends make companies develop new molecular diagnostic tests to help drive the market further. For instance, in August 2023, QIAGEN recently got approval through the U. S FDA for Thera screen PDGFRA RGQ PCR kit; this helps physicians identify patients with gastrointestinal stromal tumor (GIST). In addition, in the year of January 2023, the FDA has granted EUA for the VIASURE Monkeypox Virus Real-Time PCR Reagents manufactured by BD and CerTest Biotec for identifying the Mpox virus. In addition, increased consumer awareness and health consciousness, high standards of living and specifically, well developed healthcare infrastructure can be said to be the factors that are driving this growth.
It is also expected that the Asia-Pacific region will have the fastest growing region rate during the forecast period because of better market access, joint market player efforts to encourage more of the diagnostic market, and the huge unmet demands in the Asia – Pacific region for diagnostic markets. For instance, in August 2023 CRISPRBits and MolBio Diagnostics Indians companies signed a strategic partnership to fast change the POC diagnostics to integrate the CRISPR system in both a POC test for pathogen and genetic markers’ identification. Additionally, the increase in Next-generation sequencing (NGS), the awareness of life-threatening diseases such as Cancer, Covid-19, Tuberculosis, STDs, the trend towards more personalised medicine, and the use of Artificial intelligence & Machine learning explains the regional market expansion.
Top Market Players in Molecular Diagnostics Market are:
F. Hoffmann-La Roche Ltd. (Switzerland)
Hologic, Inc. (US)
Abbott Laboratories (US)
Illumina, Inc. (US)
Thermo Fisher Scientific Inc. (US)
bioMerieux (France)
QIAGEN (Netherlands)
Becton Dickinson And Company (US)
Grifols S.A. (Spain)
Bio-Rad Laboratories, Inc. (US)
Sysmex Corporation (Japan)
Quidel Corporation (US)
Biocartis (Belgium)
DiaSorin (Italy)
Myriad Genetics (US)
Revvity (US)
MDxHealth (Belgium)
OncoCyte Corporation (US)
Take Action Now: Secure Your Molecular Diagnostics Market Today – http://www.skyquestt.com/buy-now/molecular-diagnostics-market
Molecular Diagnostics Market Outlooks:
In May 2024, Bruker Corporation completed the acquisition of ELITechGroup for €870 million in cash excluding ELITech clinical chemistry business. A molecular diagnostics MDx, biomedical systems/specialty IVDs, Microbiology solutions and services provider ELITech posted near about EUR 150 million of FY 2023 revenues and over 80% by Consumable. The acquisition by Bruker is impressive since it brings changes and expansion to the company and situates it as an innovative infectious disease company in the IVD industry. Bruker’s MALDI Biotyper extended its portfolio in molecular diagnostics through the partnership with ELITech, which provides MDx platforms and niche MDx assays targeting niche markets.
In February 2024, Eurofins Scientific completed the purchase deal of Diatherix Laboratories, Inc. for about US$50 million with an earn out provision for specific kinds of revenue and profitability at the end of the purchase amount. This deal is expected to be closed in 30 days (about 4 and a half weeks) and will post Eurofins’ decisive step on the way to strengthening its positions in the sphere of specialty clinical diagnostics. Based in Huntsville, Alabama, Diatherix focuses has a specialized molecular diagnostics company employing the TEM-PCR™ testing of infectious diseases, providing accurate information quickly.
Forward-Looking Insights
The Molecular Diagnostics Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
